Our study demonstrated that in most cancer types, SLC1A5, SLC7A5, SLC7A11, and SLC3A2 were highly expressed and indicative of poorer survival outcomes, while the effects of changes in the expression of GLS2 and GLS depended on the type of cancer under consideration. Here, SLC3A2 is linked to cancer.